Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3NIH 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 26CNS 15Gastrointestinal 11Lymphoid 9Tumor-Agnostic 8Sarcoma 7Other solid neoplasm 7Head & Neck 6Gynecologic 5Thoracic 4Other hematologic neoplasm 4Breast 4Plasma cell 3Dermatologic 3Myeloid 1Endocrine 1

Conditions

Multiple Myeloma 3Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Hematologic Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 267Melphalan 212Calcium Dobesilate 189daratumumab 122fludarabine phosphate 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 44Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × temsirolimus × Plasma cell × Clear all
NCT02693535 2026-05-29

TAPUR

American Society of Clinical Oncology

Phase 2 Recruiting
4,200 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

M.D. Anderson Cancer Center

Phase 1 Completed
180 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT00483262 2013-11-11

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Dana-Farber Cancer Institute

Phase 1/2 Completed
63 enrolled 11 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡